论文部分内容阅读
目的探讨胸腺肽治疗复治肺结核患者的临床疗效及对T淋巴细胞亚群的影响。方法选取2012年2月—2014年1月丰城市人民医院收治的复治肺结核患者162例,随机分为对照组与观察组,各81例。对照组患者予以常规抗结核药物治疗,观察组患者在对照组基础上加用胸腺肽治疗。观察两组患者临床疗效、治疗前、治疗3个月、治疗后T淋巴细胞亚群(CD_3~+、CD_4~+、CD_8~+、CD_4~+/CD_8~+)变化情况、不良反应发生情况及复发情况。结果观察组患者总有效率高于对照组,差异有统计学意义(P<0.05);CD_3~+、CD_4~+时间与方法间有交互作用(P<0.05),时间间比较,差异有统计学意义(P<0.05),组间比较,差异有统计学意义(P<0.05),治疗3个月、治疗后观察组患者CD_3~+、CD_4~+、CD_4~+/CD_8~+高于对照组,差异有统计学意义(P<0.01),观察组患者治疗3个月CD_3~+、CD_4~+、CD_4~+/CD_8~+高于治疗前,差异有统计学意义(P<0.01),对照组患者治疗3个月、治疗后CD_3~+高于治疗前,差异有统计学意义(P<0.01);两组患者不良反应发生率、复发率比较,差异无统计学意义(P>0.05)。结论胸腺肽治疗复治肺结核患者的临床疗效显著,可改善患者免疫功能。
Objective To investigate the clinical efficacy of thymosin in the treatment of patients with relapsed pulmonary tuberculosis and its effect on T lymphocyte subsets. Methods 162 patients with re-treatment of pulmonary tuberculosis admitted in Fengcheng People’s Hospital from February 2012 to January 2014 were randomly divided into control group and observation group, with 81 cases in each group. Patients in the control group were treated with conventional anti-TB drugs, and patients in the observation group were treated with thymosin on the basis of the control group. The clinical efficacy, the changes of T lymphocyte subsets (CD_3 ~ +, CD_4 ~ +, CD_8 ~ +, CD_4 ~ + / CD_8 ~ +) and the adverse reactions in the two groups were observed before treatment and 3 months after treatment And recurrence. Results The total effective rate in the observation group was higher than that in the control group (P <0.05). The interaction between CD_3 ~ +, CD_4 ~ + and time was significant (P <0.05) (P <0.05). The difference between the two groups was statistically significant (P <0.05). After treatment for 3 months, the levels of CD_3 ~ +, CD_4 ~ + and CD_4 ~ + / CD_8 ~ + in observation group were higher than those in control group (P <0.01). The levels of CD_3 ~ +, CD_4 ~ + and CD_4 ~ + / CD_8 ~ + in the observation group were significantly higher than those before treatment (P <0.01), and the difference was statistically significant ), The control group patients treated for 3 months, CD_3 ~ + after treatment was higher than before treatment, the difference was statistically significant (P <0.01); two groups of patients with adverse reactions, the recurrence rate, the difference was not statistically significant (P > 0.05). Conclusion The therapeutic effect of thymosin on retreatment of pulmonary tuberculosis patients is significant, which can improve the immune function of patients.